Shares of Kamada Ltd (NASDAQ:KMDA) have received an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.
Analysts have set a twelve-month consensus price objective of $8.50 for the company and are predicting that the company will post $0.06 earnings per share for the current quarter, according to Zacks. Zacks has also given Kamada an industry rank of 159 out of 265 based on the ratings given to its competitors.
Several brokerages have issued reports on KMDA. Zacks Investment Research cut shares of Kamada from a “hold” rating to a “strong sell” rating in a report on Thursday, November 16th. ValuEngine upgraded shares of Kamada from a “sell” rating to a “hold” rating in a report on Friday, January 5th. Finally, Jefferies Group restated a “buy” rating and issued a $7.00 price target on shares of Kamada in a report on Thursday, October 12th.
Kamada (NASDAQ:KMDA) last issued its earnings results on Monday, November 13th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. Kamada had a negative return on equity of 1.64% and a negative net margin of 1.27%. research analysts predict that Kamada will post 0.08 earnings per share for the current year.
Several large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new stake in Kamada in the 3rd quarter worth approximately $112,000. Edmond DE Rothschild Holding S.A. boosted its stake in Kamada by 10.5% in the 2nd quarter. Edmond DE Rothschild Holding S.A. now owns 42,200 shares of the biotechnology company’s stock worth $251,000 after purchasing an additional 4,000 shares in the last quarter. Navellier & Associates Inc acquired a new stake in Kamada in the 2nd quarter worth approximately $303,000. Worth Venture Partners LLC acquired a new stake in Kamada in the 3rd quarter worth approximately $246,000. Finally, Analyst IMS Investment Management Services Ltd. boosted its stake in Kamada by 125.5% in the 3rd quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock worth $431,000 after purchasing an additional 50,000 shares in the last quarter. Institutional investors and hedge funds own 6.31% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3142705/kamada-ltd-kmda-given-average-recommendation-of-strong-buy-by-analysts.html.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.